RhumbLine Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

RhumbLine Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Buy	86,020 +9,506	+12%	+$132K	﹤0.01%	2166
2026 Q1	$1.12M	Buy	76,514 +5,787	+8%	+$92.4K	﹤0.01%	2138
2025 Q4	$545K	Sell	70,727 -11,863	-14%	-$93.6K	﹤0.01%	2614
2025 Q3	$609K	Buy	82,590 +6,640	+9%	+$34K	﹤0.01%	2561
2025 Q2	$304K	Buy	75,950 +75,159	+9,502%	+$273K	﹤0.01%	2981
2025 Q1	$2.52K	Hold	791	–	–	﹤0.01%	3966
2024 Q4	$4.23K	Hold	791	–	–	﹤0.01%	3975
2024 Q3	$4.18K	Hold	791	–	–	﹤0.01%	4003
2024 Q2	$1.44K	Hold	791	–	–	﹤0.01%	4211
2024 Q1	$1.41K	Hold	791	–	–	﹤0.01%	4117
2023 Q4	$1.39K	Hold	791	–	–	﹤0.01%	4126
2023 Q3	$1.15K	Hold	791	–	–	﹤0.01%	4169
2023 Q2	$1.81K	Buy	+791	New	+$1.64K	﹤0.01%	4229
2019 Q2	–	Sell	-17,853	Closed	-$72K	–	2976
2019 Q1	$72K	Sell	17,853 -350	-2%	-$1.48K	﹤0.01%	2896
2018 Q4	$67K	Buy	18,203 +5,570	+44%	+$38K	﹤0.01%	2920
2018 Q3	$108K	Sell	12,633 -800	-6%	-$8K	﹤0.01%	2854
2018 Q2	$147K	Buy	+13,433	New	+$150K	﹤0.01%	2809

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RhumbLine Advisers's CRVS Position: Q2 2026 in Review

RhumbLine Advisers increased its Corvus Pharmaceuticals (CRVS) stake by 12% in Q2 2026, buying an estimated $132K and bringing the position to 86,020 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2166.

RhumbLine Advisers first reported a position in CRVS in Q2 2018 and has held it in 17 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

RhumbLine Advisers held 86,020 shares of Corvus Pharmaceuticals worth $1.29M as of Q2 2026.
RhumbLine Advisers bought 9,506 Corvus Pharmaceuticals shares in Q2 2026, an estimated $132K.
Corvus Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2166 holding.
RhumbLine Advisers first reported a position in Corvus Pharmaceuticals in Q2 2018 and has held it in 17 quarters since.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.